Zealand University Hospital in Roskilde buys VibroSense Meter II - starts studies of chemotherapy and nerve damage
The Clinical Oncology Department at Zealand's University Hospital in Roskilde buys a VibroSense Meter II from VibroSense Dynamics in order to conduct two clinical studies. The signed agreement includes a purchase option to buy two additional instruments within three years. The clinical studies start on September 1, 2019 and will be made on patients with breast, ovarian and colorectal cancer. The studies aim to investigate how chemotherapy affects nerves in feet and hands.
The research agreement involves a close collaboration between the Oncology Department at Zealand University Hospital and VibroSense Dynamics. An initial pilot study with 40 patients starts on September 1 this year. The study group in this study are patients with breast, ovarian and colorectal cancer treated with Taxanes and Oxaliplatin. The aim for this study is to investigate how chemotherapy affects the tactile sensitivity of the foot sole and of fingers. In the second study planned to start in April 2020, the study group will be increased to 100 patients.
- Nerve damage caused by chemotherapy affects large patient groups treated with taxanes or platinum-based chemotherapy. This condition cannot be prevented or treated today, which causes significant problems and damage to cancer patients, for some lifelong. We look forward to investigate Multi Frequency Vibrometry and the method's great potential for early diagnosis in order to improve the treatment and to monitor the development of nerve damage caused by chemotherapy, says Professor Jörn Herrstedt, Principal Investigator and Head of Research at Clinical Oncology Department and palliative units, Roskilde and Næstved at Zealand University Hospital.
- I am very pleased with the collaboration we are now starting with Sjællands University Hospital. The research area is very interesting and the agreement shows that there is a great confidence in our instrument and our method. Research studies are a large market and an important area for the company as they can provide us with clinical evidence and open up the even larger market for compulsory health care examinations with our instrument, during and after completed chemotherapy, ”says Toni Speidel, CEO of VibroSense Dynamics AB.
Contact
Toni Speidel, VD VibroSense Dynamics AB,
Phone: +46 40 88 026
E-mail: info@vibrosense.com
www.vibrosense.com
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (public) sells and develops efficient systems to support early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. Our vision is that the VibroSense Meter shall be the golden standard instrument for neurological examinations to assess sensory neuropathy and help to improve life conditions for patients having a risk of getting nerve injuries.